HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

N-(2-hydroxypropyl)methacrylamide co-polymer-doxorubicin conjugate

RN in first source; PK1 (FCE-28068) is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker; in phase II trials for breast, non-small-cell lung and colon cancers (6/2003)
Also Known As:
FCE-28068; FCE28068; HPMA-co-polymer-doxorubicin conjugate; PK1 compound
Networked: 3 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Duncan, Ruth: 2 articles (06/2009 - 01/2007)
2. Schatzlein, Andreas: 1 article (06/2009)
3. Boivin, Christopher: 1 article (06/2009)
4. Calvert, Hilary: 1 article (06/2009)
5. Seymour, Leonard W: 1 article (06/2009)
6. Blackie, Robert: 1 article (06/2009)
7. Hesslewood, Stuart: 1 article (06/2009)
8. Kerr, David J: 1 article (06/2009)
9. Jodrell, Duncan: 1 article (06/2009)
10. Ferry, David R: 1 article (06/2009)

Related Diseases

1. Colorectal Neoplasms (Colorectal Cancer)
2. Neoplasms (Cancer)
3. Colonic Neoplasms (Colon Cancer)
4. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. Polymers
2. Doxorubicin (Adriamycin)
3. methacrylamide
4. hydroxypropyl methacrylate

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)